{"entity":{"id":"nct07083323","kind":"trial","name":"A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of HY05350 for injection in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.","summary":"A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07083323 by Sichuan Huiyu Pharmaceutical Co., Ltd, with 262 participants planned, started 2025-07-22 and due to reach its primary completion in 2028-03-31. Interventions recorded: HY05350 for injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07083323","url":"https://clinicaltrials.gov/study/NCT07083323"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07083323","phase":"1/2","setting":"A Multicenter, Open-label Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Clinical Efficacy of HY05350 for Injection in Patients With MSLN-positive Advanced Solid Tumors","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","enrolled":262,"outcomes":[]},"route":"/trials/nct07083323/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}